# US 2014/0271624 A1 · Anti-notch nrr antibodies and methods using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0271624 A1
- Document ID: US20140271624A1
- Status: Published application
- Kind: A1
- Application number: 14/177,452
- Filed: 2014-02-11
- Published: 2014-09-18
- Earliest claimed: 2007-06-04
- Assignees: Genentech, Inc.
- Applicants: Genentech, Inc.
- Inventors: Christian W. Siebel; Yan Wu
- Web page: https://patentgrep.com/patent/US20140271624A1

## CPC

- C07K 16/30: from tumour cells
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 19/00: Drugs for skeletal disorders
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/18: against material from animals or humans
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/3015: {Breast}
- C12N 5/10: Cells modified by introduction of foreign genetic material
- C12N 15/09: Recombinant DNA-technology
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K 2039/505: {comprising antibodies}
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/71: for growth factors; for growth regulators
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C12N 5/12: Fused cells, e.g. hybridomas
- C12N 2330/50: Biochemical production, i.e. in a transformed host cell
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides anti-Notch1 NRR antibodies, and compositions comprising and methods of using these antibodies.

## Claims

### Claim at position 1

-31. (canceled)

### Claim 32

A method for treating a disorder associated with increased Notch1 signaling or expression in an individual, the method comprising administering an effective amount of a monoclonal anti-Notch1 negative regulatory region (NRR) antibody to the individual, wherein the antibody binds Notch1 NRR comprising amino acids 1447-1733 of SEQ ID NO:56.

### Claim 33 (depends on 32)

The method of claim 32, wherein said disorder is a cancer.

### Claim 34 (depends on 33)

The method of claim 33, wherein said cancer is a breast cancer.

### Claim 35 (depends on 33)

The method of claim 33, wherein said cancer is a colon cancer.

### Claim 36 (depends on 33)

The method of claim 33, wherein said cancer is a T-cell acute lymphoblastic leukemia (T-ALL).

### Claim 37 (depends on 32)

The method of claim 32, further comprising administering to the individual an effective amount of a second medicament, wherein the anti-Notch1 NRR antibody is a first medicament

### Claim 38 (depends on 37)

The method of claim 37, wherein the second medicament is another antibody, a chemotherapeutic agent, a cytotoxic agent, an anti-angiogenic agent, an immunosuppressive agent, a prodrug, a cytokine, a cytokine antagonist, cytotoxic radiotherapy, a corticosteroid, an anti-emetic, a cancer vaccine, an analgesic, or a growth-inhibitory agent.

### Claim 39 (depends on 37)

The method of claim 37, wherein the second medicament is tamoxifen, letrozole, exemestane, anastrozole, irinotecan, cetuximab, fulvestrant, vinorelbine, erlotinib, bevacizumab, vincristine, imatinib, sorafenib, lapatinib, or trastuzumab.

### Claim 40 (depends on 37)

The method of claim 37, wherein the second medicament is administered prior to or subsequent to the administration of the anti-Notch1 NRR antibody.

### Claim 41 (depends on 37)

The method of claim 37, wherein the second medicament is administered concurrently with the anti-Notch1 NRR antibody.

### Claim 42 (depends on 32)

The method of claim 32, wherein Notch1 expression or a Notch1 ligand expression is determined in a biological sample of the individual before, during or after administration of the anti-Notch1 NRR antibody.

### Claim 43 (depends on 32)

The method of claim 32, wherein said individual is a human.

### Claim 44 (depends on 32)

The method of claim 32, wherein said anti-Notch1 NRR antibody binds human Notch1 NRR with a Kd of 1×10−7 or stronger.

### Claim 45 (depends on 32)

The method of claim 32, wherein the antibody comprises HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3, wherein each, in order, comprises SEQ ID NO:7, 8, 9, 1, 2, 6.

### Claim 46 (depends on 32)

The method of claim 32, wherein the antibody comprises HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3, wherein each, in order, comprises SEQ ID NO:7, 8, 10, 1, 3, 6.

### Claim 47 (depends on 32)

The method of claim 32, wherein the antibody comprises HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3, wherein each, in order, comprises SEQ ID NO:7, 8, 11, 1, 4, 6.

### Claim 48 (depends on 32)

The method of claim 32, wherein the antibody comprises HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3, wherein each, in order, comprises SEQ ID NO:7, 8, 12, 1, 5, 6.

### Claim at position 19

-104. (canceled)

### Claim 105 (depends on 32)

The method of claim 32, wherein the antibody induces cancer cell differentiation.

### Claim 106 (depends on 32)

The method of claim 32, wherein the antibody reduces tumor angiogenesis.

### Claim 107 (depends on 32)

The method of claim 32, wherein the cancer is associated with an activating mutation in Notch 1.

### Claim 108 (depends on 32)

The method of claim 32, wherein the antibody comprises a heavy chain variable region sequence of SEQ ID NO:58, 60, 62 or 64, and a light chain variable region sequence of SEQ ID NO:59, 61, 63 or 65.

### Claim 109 (depends on 32)

The method of claim 32, wherein the antibody competes for binding to human Notch1 NRR with an antibody comprising HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3, wherein each, in order, comprises SEQ ID NO:7, 8, 9, 1, 2, 6.

### Claim 110 (depends on 32)

The method of claim 32, wherein the antibody competes for binding to human Notch1 NRR with an antibody comprising HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3, wherein each, in order, comprises SEQ ID NO:7, 8, 10, 1, 3, 6.

### Claim 111 (depends on 32)

The method of claim 32, wherein the antibody competes for binding to human Notch1 NRR with an antibody comprising HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3, wherein each, in order, comprises SEQ ID NO:7, 8, 11, 1, 4, 6.

### Claim 112 (depends on 32)

The method of claim 32, wherein the antibody competes for binding to human Notch1 NRR with an antibody comprising HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3, wherein each, in order, comprises SEQ ID NO:7, 8, 12, 1, 5, 6.

### Claim 113 (depends on 32)

The method of claim 32, wherein the antibody competes for binding to human Notch1 NRR with an antibody comprising a heavy chain variable region sequence of SEQ ID NO:58, 60, 62 or 64, and a light chain variable region sequence of SEQ ID NO:59, 61, 63 or 65.

### Claim 114 (depends on 32)

The method of claim 32, wherein the antibody decreases Notch 1 signaling.

### Claim 115 (depends on 114)

The method of claim 114, wherein decreased Notch1 signaling is measured using a luciferase reporter assay.

### Claim 116 (depends on 115)

The method of claim 115, wherein the antibody decreases Notch1 signaling by at least three fold below levels observed in the absence of the antibody.

### Claim 117 (depends on 114)

The method of claim 114, wherein the antibody reduces signaling to about 18% of signaling in the absence of the antibody.

### Claim 118 (depends on 114)

The method of claim 114, wherein the Notch1 signaling is ligand-mediated Notch1 signaling.

### Claim 119 (depends on 118)

The method of claim 118, wherein the ligand is Jagged1.

### Claim 120 (depends on 32)

The method of claim 32, wherein the antibody competes with Antibody A, Antibody A-1, Antibody A-2, or Antibody A-3 for binding to human Notch1 NRR.

### Claim 121 (depends on 32)

The method of claim 32, wherein the antibody binds to an epitope within the Notch1 NRR recognized by any one of Antibody A, Antibody A-1, Antibody A-2, or Antibody A-3.

### Claim 122 (depends on 44)

The method of claim 44, wherein the Kd is determined by a surface plasmon resonance assay.

### Claim 123 (depends on 44)

The method of claim 44, wherein the Kd is determined by a radiolabeled antigen binding assay.

### Claim 124 (depends on 32)

The method of claim 32, wherein the antibody is a humanized or chimeric antibody.
